Reduced-intensity conditioning (RIC) preparative regimens are now widely used in umbilical cord blood (UCB) transplantation. Developed to reduce the rate of transplant-related morbidity and mortality as in adult stem cell donor transplantation, they are becoming more widely accepted. Results from RIC UCB series show a shortened time to engraftment, ranging from 12 to 24 days, with rates of TRM that generally do not exceed the rates seen with myeloablative UCB transplantation. There does not seem to be a convincing trend toward an increase in the rate of malignant relapse after RIC UCB transplantation, despite the lower intensity of the conditioning regimen. In this review, the results from several RIC UCB series are reviewed, comparisons with myeloablative UCB experiences are made and hypotheses regarding the engraftment potential of UCB after RIC regimens are discussed. In addition, a strategy for the optimal use of RIC regimens and UCB transplantation is presented.
Introduction
The dominant rationale for the use of reduced-intensity conditioning (RIC) preparative regimens in adult and umbilical cord blood (UCB) SCT is the potential for a reduction in the morbidity and mortality associated with myeloablative conditioning, which is similar to the rationale in related and unrelated adult donor SCT. That insufficient conditioning intensity would be detrimental to engraftment has always been the largest concern, preventing the widespread adoption of this technique, particularly in UCB transplantation in which there is an obligate reduction in the hematopoietic stem cell dose delivered. These concerns have largely been shown to be false, and there has been a gradual adoption of the use of RIC regimens in UCB transplantation. In this article, we review the rationale for RIC preparative regimens, and also the major outcomes associated with RIC transplantation. As a working definition, we use the term RIC to mean all regimens the intensity of which is less than a traditionally defined myeloablative preparative regimen.
RIC UCB transplantation: clinical trials
On the basis of the hypothesis that T-cell alloreactivity in UCB grafts would be sufficient to effect donor engraftment, Barker et al. performed one of the largest pilot trials of RIC transplantation in adults. Using a dose de-escalation strategy, 43 patients were treated with fludarabine, TBI (200 cGy) and either BU (8 mg/kg total, n ¼ 21) or CY (50 mg/kg, n ¼ 22). Over half of the patients received two UCB units, and all patients received GVHD prophylaxis with CYA and mycophenolate mofetil. Almost all of the units were mismatched at one or two HLA loci, and the median CD34 þ dose infused was 3.7 Â 10 5 cells/kg (BU group) or 4.3 Â 10 5 cells/kg (CY group). Although primary engraftment occurred in similar proportions in both groups (88 and 94%, respectively), there was a substantial rate of graft loss only in the BU group with only 76% having sustained engraftment at day 42, in comparison with 94% in the CY group (Po0.01). These differences in engraftment lead to substantial differences in treatment-related mortality and OS, with the CY group having superior outcomes at 1 year (24 vs 41% survival). 1 The engraftment data shown here are at least in part related to the use of two sequentially administered unrelated UCB units as a method of increasing the delivered CD34 þ stem cell dose. A more recent update of the Minnesota experience has recently been published. In this series of 110 individuals, 85% received two UCB units. The same fludarabine/CY/ TBI RIC regimen as in the earlier report was used. In total, 15 patients failed to engraft or subsequently had graft rejection (13.6%), and the median time to engraftment in the remaining individuals was 12 days. Only 65% engrafted plts by day 180. Chimerism was mixed at early time points after transplantation, but converted to single donor by 1 year in all surviving patients. Grades II-IV acute GVHD occurred in 59% of patients, with chronic GVHD noted in 23% of patients. Overall, 19% of patients died of TRM by 6 months, with EFS at 3 years of 38%, with better results noted in the double UCB transplant group when compared with the single UCB group. ) and anti-thymocyte globulin (6 mg/kg) have now been completed. In these trials, 53 subjects received two UCB units, matched at 4/6 HLA loci or better to each other and to the recipient. GVHD prophylaxis regimens were CYA and mycophenolate mofetil (cohort 1, n ¼ 21) 3 ) pre-cryopreservation, without cohort differences. Engraftment kinetics did not differ based on GVHD prophylaxis, with neutrophil engraftment at a median of 20 days (range 13-70) and plt engraftment (to 20 000 per ml) at a median of 41 days (range 21-185). In total, five patients experienced graft loss between days 35 and 102. As a result of rapid engraftment, 100-day treatment-related mortality was only 12%. Grades II-IV acute GVHD occurred in 20% of subjects (33% cohort 1, 10% cohort 2, P ¼ 0.05). Chronic GVHD occurred in 24%, without cohort differences. 4 In a non-competing risk analysis, the incidence of relapse was 28.3%. With a median follow-up among survivors of 3 years, the long-term relapse-free and OS of the entire cohort are 24.6 and 33.1%, respectively. As a result of these two studies, sequential double UCB transplantation with RIC has become the preferred conditioning regimen at the Dana Farber Cancer Center and Massachusetts General Hospital, when UCB transplantation is required.
Many of the early reports of umbilical SCT using RIC were case reports or case series. For example, in one of the earliest published reports, the Duke group presented outcome data on two patients. 5 More contemporary series include a larger number of patients. The largest of these is from the Japanese group, who reported on 12 patients who underwent single UCB transplantation using fludarabine (200 mg/m 2 ), CY (50 mg/kg) and TBI (3 Gy) as preparation. Treatment-related mortality in this series was high, with 40% of engrafting patients succumbing by 100 days. 6 A summary of the major clinical findings in other RIC UCB transplantation trials can be found in Table 1 .
RIC UCB transplantation: treatment-related mortality
The treatment-related mortality noted in our trials (12% at 100 days) as well as in the Minnesota experience (19% at 180 days) suggests that TRM may be reduced when a RIC approach is used, as much higher rates of TRM have been reported after the use of myeloablative regimens. [7] [8] [9] For example, Okada et al. reported a 24% rate of 100-day TRM when a conditioning regimen of fludarabine, cytarabine and TBI (12 Gy) was used in a cohort of 38 patients with a variety of hematological malignancies. The predominant cause of death was infection, presumably related to delayed engraftment. At 1 year, over a third of patients had died of TRM. 8 Lekakis et al. 7 report a 40% incidence of 100-day TRM after fludarabine and TBI (12 Gy) conditioning. Finally, Sanz et al. 9 reported a 43% incidence of TRM at 100 days after a conditioning regimen of thiotepa, BU, CY and anti-thymocyte globulin. All of these trials transplanted subjects with single UCB units, whereas the Minnesota group as well as our own experience is predominantly a double UCB experience, which may account for some of the differences in TRM.
Comparisons between RIC UCB and RIC adult SCT, with one exception, have not been performed. The one retrospective comparison involved patients above the age of 55 years who underwent either RIC UCB transplantation and were compared with a cohort of patients who underwent matched, related donor RIC transplantation. The RIC UCB patients represent a subset of the previously reported Minnesota series. In this comparison, rates of TRM were equivalent between UCB and matched-related donor stem cell recipients. 10 Comparisons of outcome have been performed in the myeloablative setting, and they suggest that TRM after myeloablative UCB transplantation is increased when compared with matched-unrelated donors in one review, 11 but not another. 12 The series by Laughlin et al. reported higher than the expected rates of TRM in 68 individuals transplanted for malignant and non-malignant conditions. In this series, 11% of patients died of regimen-related toxicity or infection by day 28, and an additional 38% died of regimen-related toxicity, infection or GVHD between day 28 and 100. In total, 50% of patients died within 3 months of receiving a myeloablative preparative regimen, not including one patient who succumbed to relapse. 13 Thus, it does seem likely that the rates of TRM after RIC UCB transplantation are lower than after myeloablative UCB transplantation. Aside from the obvious explanation that conditioning-related injury is largely responsible is the possibility that in a minority of patients with primary graft failure, outcomes are improved after RIC UCB transplantation because of the increased potential for autologous hematopoietic recovery, which is very unlikely after myeloablative conditioning. This hypothesis is only speculative, and can account for only a small portion of the differences noted in outcomes.
RIC preparative regimens: engraftment requirements
It seems that all reduced-intensity regimens may not permit engraftment of UCB units. For example, a non-TBI, nonanti-thymocyte globulin(ATG)-containing regimen of fludarabine and melphalan was insufficient immunosuppression to promote engraftment in 5 of 10 treated individuals.
14 In fact, even more myeloablative doses of fludarabine and BU were not capable of promoting sustained engraftment after UCB transplantation. 15, 16 In the Mexican non-TBI, non-ATG experience, the rate of non-engraftment was higher in patients who had non-malignant conditions (71%) in comparison with patients who had a malignancy (28%). 17 Although both rates are unacceptably high, this difference points to the importance of T-cell immunosuppression to promote engraftment, which is best afforded by agents such as ATG or the use of TBI. This requirement is shown by the results of the Minnesota series, in which TBI (200 cGy) was administered to all recipients, and in which recently chemo-naive patients (35%) also received ATG. In this series, sustained engraftment was noted in 85% of individuals, whereas in our series, in which all patients received ATG (6 mg/kg rabbit ATG), sustained engraftment has now been shown in 89% of the transplanted individuals. Similarly, other smaller series have shown high rates of engraftment when either ATG or TBI are employed. 6, 18, 19 There is a paucity of data for comparison of engraftment times between reduced-intensity and myeloablative transplantation. A median time to engraftment of 12 days was noted in the Minnesota series, in which 85% of patients received two UCB units, and the median time in our own double UCB series was 21 days. 4 A summary of the engraftment times for reduced-intensity UCB transplantation studies is shown in Table 1 . For comparison, the two largest retrospective reviews of myeloablative single UCB transplantation reported median times to neutrophil engraftment of 26 and 27 days. 11, 12 Although this difference may be due to the increase in transplanted nucleated or CD34 þ progenitor cell dose, there may have been an independent effect of the conditioning regimen as well, on the basis of CD34 þ progenitor trafficking to the marrow niche.
It has been shown that tissue injury from lethal doses of irradiation can impair specific homing of progenitors. 20 Trafficking of progenitors to the marrow space requires the recognition of specific chemokine-receptor interactions at the level of the progenitor cell. The best characterized of these interactions is between the chemokine receptor CXCR4 and its ligand, SDF-1a. 21 It has been shown in animal models that in response to injury, SDF-1a may be upregulated. This, in turn, may result in retention of circulating CXCR4 þ hematopoeitic progenitors in non-marrow spaces, thus impairing engraftment. This impaired homing could be reversed by the administration of a specific inhibitor of the SDF-1a-CXCR4 interaction. 22, 23 Similarly, delaying transplantation of hematopoietic progenitors after conditioning could also improve hematopoietic homing, suggesting that the injury associated with conditioning therapy and upregulation of SDF1a is reversible. 24 These data overall would suggest that conditioning-related injury may impair engraftment of hematopoietic progenitors. The use of reduced-intensity therapy, however, may result in less tissue damage than myeloablative conditioning, and may in fact be associated with superior engraftment after transplantation of umbilical cord stem cells.
RIC UCB transplantation: relapse incidence
With a presumed reduction in the efficacy of the graft vs tumor effect due to fewer T cells in an UCB product, one could assume that conditioning intensity might have an important role in the relapse prevention after UCB SCT. The intensity of the conditioning regimen has been shown to have an important role in adult SCT, in which comparisons between minimally intensive non-myeloablative regimens with myeloablative chemoradiotherapy have shown statistically significantly increased rates of relapse in both myeloid 25 and lymphoid 26 malignancies. It is difficult to anticipate whether this relationship will hold true in UCB transplantation. There are no prospective trials either performed or currently being planned to assess the impact of conditioning intensity in UCB transplantation. Retrospective database reviews, unless very large, are subject to bias because the distribution of malignant diseases and their stage at the time of transplantation are unlikely to be distributed evenly. With the relationship of conditioning intensity in adults in mind, it is difficult to extrapolate this to UCB transplantation. This is largely because the majority of RIC regimens in UCB transplantation still contain chemotherapeutic agents at levels that are close to ablative intensity. For example, the Boston regimen uses melphalan at 100 mg/m 2 in combination with other agents and the Minnesota regimen uses CY (50 mg/kg) in combination with fludarabine (200 mg/m 2 ). Although nonablative, these regimens are expected to provide substantial anti-tumor activity, in comparison to the truly nonmyeloablative options used with adult stem cells.
RIC UCB transplantation: optimal use
It is our practice to offer UCB transplantation to any individual in whom an unrelated allogeneic stem cell transplant is indicated, and in whom a perfectly matched adult stem cell donor cannot be found, or cannot be used in a reasonable time period. There are currently no widely accepted scenarios in which the use of UCB should be used as the preferred stem cell source for adults when a fully HLA-matched, related or unrelated donor is readily available for donation. However, when UCB stem cells are required, a decision on the intensity of conditioning must be made. Given the increase in mortality associated with myeloablative regimens, we use RIC conditioning in almost all patients, except those with refractory malignancies below the age of 40. The use of very low-intensity conditioning regimens with UCB stem cells is discouraged, given the high rates of graft failure and should be limited to those patients in whom even modest doses of chemotherapy are expected to be poorly tolerated. Thus, we would suggest the use of a moderately intense but non-myeloablative regimen as optimal for the majority of the patients requiring UCB SCT to maximize treatment outcomes.
